Eli Lilly’s weight-loss pill meets target in key diabetes trial

August 26, 2025

•

1 min read

•

Financial Times

Results from US pharma group show oral drug reduced body weight by 10.5% on average

US pharmaceutical group Eli Lilly has announced that the latest trial of its anti-obesity pill has met weight-loss targets, boosting its plans to seek approval for the drug as it fights for market dominance with rival Novo Nordisk. Lilly said on Tues... [2255 chars]

Read Original Article

Source: Financial Times

Visit Source

Share this article

Twitter Facebook

Back to general news